Balefire LLC Lowers Position in Sotera Health Company $SHC

Key Points

• Balefire LLC cut its Sotera Health position by 56.7% in the second quarter, selling 58,401 shares and retaining 44,533 shares valued at approximately $790,000. Institutional investors and hedge funds collectively own 91.03% of SHC.
• Sotera Health exceeded second-quarter expectations, reporting adjusted EPS of $0.26 and revenue of $321.4 million, up 9.2% year over year. Management also raised its 2026 guidance and cited broad-based segment growth, improved margins, and lower leverage.
• SHC shares opened at $18.91, near their 52-week high, while analysts maintain a “Moderate Buy” consensus with an average price target of $20.25.

Balefire LLC trimmed its holdings in shares of Sotera Health Company (NASDAQ:SHC - Free Report) by 56.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 44,533 shares of the company's stock after selling 58,401 shares during the quarter. Balefire LLC's holdings in Sotera Health were worth $790,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Empowered Funds LLC lifted its position in Sotera Health by 11.1% in the first quarter. Empowered Funds LLC now owns 28,512 shares of the company's stock valued at $332,000 after buying an additional 2,845 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Sotera Health by 14.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company's stock valued at $3,999,000 after acquiring an additional 43,471 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Sotera Health by 125.5% during the first quarter. Acadian Asset Management LLC now owns 25,192 shares of the company's stock valued at $293,000 after acquiring an additional 14,018 shares during the last quarter. Creative Planning raised its stake in shares of Sotera Health by 15.3% in the 2nd quarter. Creative Planning now owns 20,186 shares of the company's stock valued at $224,000 after acquiring an additional 2,673 shares during the period. Finally, Invesco Ltd. raised its stake in shares of Sotera Health by 4.2% in the 2nd quarter. Invesco Ltd. now owns 319,156 shares of the company's stock valued at $3,549,000 after acquiring an additional 12,758 shares during the period. 91.03% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Sotera Health

In other news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of the company's stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $15.17, for a total transaction of $193,194,516.17. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 15.36% of the stock is currently owned by company insiders.

Key Stories Impacting Sotera Health

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Second-quarter adjusted EPS was $0.26, above the $0.24 consensus estimate and up 30% from $0.20 a year earlier. Revenue rose 9.2% year over year to $321.4 million, exceeding estimates of $309.7 million. Sotera Health Company Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its 2026 outlook to constant-currency revenue growth of 5.25%–6.75%, adjusted EBITDA growth of 5.75%–7.25%, and adjusted EPS of $0.95–$1.01. The EPS range begins in line with consensus and provides potential upside if execution remains strong. Sotera Health Delivers Strong Second-Quarter Results and Raises Outlook
• Positive Sentiment: Growth was broad-based: Sterigenics revenue increased 7.0% on a constant-currency basis, Nordion grew 16.7%, and Nelson Labs grew 5.4%. Adjusted EBITDA rose 10% and margin expanded to 51.6%.
• Positive Sentiment: Financial flexibility improved as the company repriced its term loan, expects roughly $3.5 million in annual interest savings, and reduced its net leverage ratio to 3.0x from 3.2x. It reported approximately $950 million of available liquidity and no revolver borrowings.

Sotera Health Trading Up 5.2%

NASDAQ SHC opened at $18.91 on Friday. The firm has a 50 day simple moving average of $17.07 and a 200-day simple moving average of $16.31. The company has a debt-to-equity ratio of 3.56, a quick ratio of 2.54 and a current ratio of 2.82. Sotera Health Company has a one year low of $11.12 and a one year high of $19.85. The firm has a market cap of $5.39 billion, a price-to-earnings ratio of 46.12 and a beta of 1.77.

Sotera Health (NASDAQ:SHC - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of $0.24 by $0.02. The firm had revenue of $321.38 million during the quarter, compared to analysts' expectations of $309.70 million. Sotera Health had a net margin of 9.91% and a return on equity of 39.73%. The business's quarterly revenue was up 9.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.20 earnings per share. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. Equities research analysts anticipate that Sotera Health Company will post 0.87 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on SHC. UBS Group set a $19.00 price objective on shares of Sotera Health in a research report on Wednesday, June 24th. Piper Sandler reissued an "overweight" rating and issued a $22.00 target price (down from $24.00) on shares of Sotera Health in a research report on Wednesday, May 6th. The Goldman Sachs Group initiated coverage on Sotera Health in a research note on Friday, June 5th. They set a "buy" rating and a $20.00 price target on the stock. Barclays raised their price target on Sotera Health from $18.00 to $19.00 and gave the stock an "overweight" rating in a research report on Wednesday, June 24th. Finally, Weiss Ratings raised Sotera Health from a "hold (c-)" rating to a "hold (c)" rating in a research note on Thursday, July 9th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $20.25.

About Sotera Health

Sotera Health Inc NASDAQ: SHC is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source